SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Eli Lilly and Company and Incyte Corporation's Oral JAK1 and JAK2 Inhibitor, Baricitinib, Showed Positive Results in Phase IIb Study in Patients with Active Rheumatoid Arthritis